A Nanocrystal Biosensor for Detection of Multiple TBI Neurochemical Biomarkers

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$199,984.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS056848-01A1
Agency Tracking Number:
NS056848
Solicitation Year:
2007
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOMATERIALS AND NANOFABRICATION LABS
NANOMATERIALS AND NANOFABRICATION LABS, P.O. BOX 2168, FAYETTEVILLE, AR, 72702
Hubzone Owned:
N
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
030498609
Principal Investigator
 YONGCHENG LIU
 (479) 575-3481
 ycliu@nn-labs.com
Business Contact
 YONGCHENG LIU
Phone: (479) 575-2723
Email: ycliu@nn-labs.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This SBIR proposal intends to develop a nanocrystal biosensor, which is capable of simultaneously detecting and quantifying multiple traumatic brain injury (TBI)-specific biomarkers in relatively small volumes of whole blood (0.1-1 uL). The biosensor design utilizes the well-known size dependent photoluminescence (PL) of the semiconductor nanocrystals to label monoclonal antibodies for these brain injury-specific biomarkers such as {S-100a, D- Dimer, and CRP, etc}. The semiconductor nanocrystals as biolabels make the biosensor able to simultaneously detect multiple TBI-specific neurochemical biomarkers in one setup with a single light source due to their broad excitation spectra, and their narrow, symmetric emission spectra. A membrane filter, immobilized with multiple monoclonal antibodies, will be used as a bioseparator to specifically capture and separate these multiple TBI-specific neurochemical biomarkers from the sample while going through the microflow cell. The simultaneous detection and quantification of multiple brain injury-specific biomarkers will subsequently be accomplished by the differently sized semiconductor nanocrystal biolabeled antibodies. The simultaneous detection of multiple TBI-specific neurochemical biomarkers diminishes the false signal and improves the accuracy in assessing TBI. In comparison to existing technologies such as ELISA, this new technology will be more sensitive, reliable, specific, accurate, portable, robust, inexpensive and rapider to assess TBI.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government